AstraZeneca’s Farxiga and Xigduo XR Receives FDA’s Expanded Label Approval for Type 2 Diabetes (T2D) and Moderate Renal Impairment

 AstraZeneca’s Farxiga and Xigduo XR Receives FDA’s Expanded Label Approval for Type 2 Diabetes (T2D) and Moderate Renal Impairment

AstraZeneca’s Farxiga and Xigduo XR Receives FDA’s Expanded Label Approval for Type 2 Diabetes (T2D) and Moderate Renal Impairment

Shots:

  • The expanded label approval is based on P-III DERIVE study results assessing Farxiga (dapagliflozin 10 mg) vs PBO in patients with type 2 diabetes (T2D) with moderate renal impairment
  • P-III DERIVE study results: reduction in HbA1c with safe results (-0.37% vs -0.03%), reduced mean body weight (-3.17kg vs -1.92kg), reduced mean fasting plasma glucose ((-21.46 mg/dL vs -4.87 mg/dL), reduced mean systolic blood pressure (-4.8 mm Hg vs -1.7 mm Hg)
  • Farxiga (dapagliflozin) is an SGLT2 inhibitor targeted as an adjunct to diet and exercise to improve glycemic control in adults with T2D mellitus

Click here to read full press release/ article | Ref: Business Wire | Image: Financial Times

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post